Eli Lilly Shares Jump 6% on EU Panel Nod for Jaypirca Expansion

Shares of Eli Lilly and Co (NYSE:LLY) rose nearly 6% on Friday after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended expanding the approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy.

Details of the Recommendation

The CHMP recommended expanding Jaypirca's indication to include treatment of CLL in adults who have received prior therapy or are treatment-naïve. Jaypirca is a non-covalent BTK inhibitor that has shown efficacy in patients resistant to other treatments.

Company's Response

Eli Lilly welcomed the recommendation, calling it an important step toward providing a new treatment option for patients in Europe. The European Commission is expected to issue a final decision within months.

Regulatory Context

This recommendation follows the U.S. FDA approval of Jaypirca for CLL in December 2025. Chronic lymphocytic leukemia is one of the most common types of leukemia in adults.

Potential Financial Impact

Expanding the indication could significantly boost Jaypirca sales, which reached $1.2 billion in 2025. However, the company has not provided specific revenue guidance from this expansion.